Q4 2025 Abbott Laboratories Earnings Call Transcript

Jan 22, 2026 / 02:00 PM GMT

Release Date Price: MXN1900 (-15.71%)

Transcript 8-K

Key Points

Positve

Abbott Laboratories (ABT) achieved double-digit earnings per share growth in 2025 despite market challenges.
The company has a strong pipeline with several new product launches planned, including in the diabetes care and structural heart segments.
Abbott Laboratories (ABT) is making strategic acquisitions, such as Exact Sciences, to enter and lead in the cancer diagnostics market.
The medical devices segment saw a 10.5% sales growth, driven by innovations in diabetes care and electrophysiology.
The company is focusing on innovation and operational excellence to sustain high single-digit to low double-digit growth in 2026.

Negative

The nutrition segment faced challenges with sales decline due to market share loss and increased manufacturing costs.
Abbott Laboratories (ABT) experienced a 3.5% decline in diagnostics sales due to reduced COVID-19 testing demand.
The company is facing headwinds in China, impacting its core diagnostics business.
There is a need to reignite volume growth in the nutrition segment, which may affect short-term results.
The company is adjusting pricing strategies in response to consumer price sensitivity, which could impact near-term profitability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ABT.N - Abbott Laboratories
Q4 2025 Abbott Laboratories Earnings Call
Jan 22, 2026 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and thank you for standing by.

Welcome to Abbott's 4th quarter, 2025 earnings conference call.

All participants will be able to listen-only until the question-and-answer portion of this call.

During the question-and-answer session, you will be able to ask your question by pressing the 11 keys on your touchstone phone.

This call is being recorded by Abbott, with the exception of any participants' questions asked during the question-and-answer session.

The entire call, including the question-and-answer session, is material copyrighted by Abbott.

It cannot be recorded or rebroadcast without Abi Express written permission.

I would now like to introduce Mr.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.